A study to develop a prospective multi-site registry to evaluate clinical features, types of treatment, outcomes and survival in participants with HER2 positive metastatic breast cancer managed in routine practice in Australia.
- Patients of any age, gender and ECOG performance status diagnosed with HER2+ metastatic breast cancer, of any hormone receptor status, either recurrent or de novo metastatic disease, since 24 February 2015
- Histological or cytological confirmation of breast cancer diagnosis and confirmation of HER2 positivity
- Commencement of 1st or 2nd line therapy on or after 24 February 2015
This is an observational/non-interventional study. The factors to be observed include the type of clinical characteristics of participants, such as age at diagnosis, performance status, and comorbidities; the type of tumour characteristics such as rate of hormone receptor positivity, sites of metastatic disease at diagnosis, rate of brain metastases at any time during the disease course, and time to relapse in participants with past history of early stage breast cancer; treatment patterns including the choice of HER2 agent for 1st, 2nd and 3rd line settings, choice of chemotherapy agent to be used in combination with HER2 therapy, and rate of treatment with trastuzumab beyond disease progression; and survival including overall survival and progression free survival in 1st, 2nd and 3rd line settings.